A Randomized Open-Label Multicenter Phase 3 Trial of Domvanalimab Zimberelimab and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously-Untreated Locally Advanced Unresectable or Metastatic Gastric Gastroesophageal Junction and Esophageal Adenocarcinoma

Brief description of study

This study is designed for patients who have Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

This is a phase 3, randomized, open-label, multicenter trial for patients with previously-untreated locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma. Participants will be randomized to one of two study treatments: Domvanalimab, Zimberelimab and chemotherapy OR Nivolumab and chemotherapy.


Clinical Study Identifier: s22-00835
Principal Investigator: Jennifer Chuy.
Other Investigators: Daniel J Becker, Marta Wioleta Wronska, Paul E. Oberstein, Kristen Spencer, Monica Rivera, Keriann M Scavone, Nina Beri, Anastasiya Apanasyuk, Michael Shusterman, Rafael Winograd, Shun Yu, Alexander A Hindenburg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.